3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
71
Colorectal Neoplasms
34
Rectal Neoplasms
33
Esophageal Neoplasms
25
Carcinoma, Non-Small-Cell Lung
24
Esophageal Squamous Cell Carcinoma
23
Pancreatic Neoplasms
16
Stomach Neoplasms
15
Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Adenocarcinoma Of Esophagus
14
Sarcoma
11
Ovarian Neoplasms
11
Lung Neoplasms
11
Colonic Neoplasms
11
Carcinoma, Hepatocellular
11
Prostatic Neoplasms
10
Head and Neck Neoplasms
10
Neoplasm Metastasis
9
Urinary Bladder Neoplasms
8
Uterine Cervical Neoplasms
7
Recurrence
6
Osteosarcoma
6
Multiple Myeloma
5
Fallopian Tube Neoplasms
5
Carcinoma, Intraductal, Noninfiltrating
5
Breast Carcinoma In Situ
5
Peritoneal Neoplasms
4
Nasopharyngeal Carcinoma
4
Locally Advanced Rectal Cancer
4
Interventions
Pemetrexed
9
Drug Therapy
9
osimertinib
7
Radiotherapy
6
Carboplatin
6
anlotinib
5
Radiosurgery
5
aflutinib
4
Gefitinib
4
Docetaxel
4
Cisplatin
4
tislelizumab
3
pembrolizumab
3
icotinib
3
Vinorelbine
3
Paclitaxel
3
Gemcitabine
3
Erlotinib Hydrochloride
3
toripalimab
2
dacomitinib
2
camrelizumab
2
apatinib
2
Tyrosine Kinase Inhibitors
2
Thalidomide
2
Surgical Procedures, Operative
2
S 1 (combination)
2
Platinum
2
Liquid Biopsy
2
Immune Checkpoint Inhibitors
2
Chemotherapy, Adjuvant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
NSCLC
×
Neoadjuvant Therapy
×
Clear all
NCT07089199
2025-07-28
TitAN
Qilu Hospital of Shandong University
Phase 2
Not yet recruiting
34 enrolled